Vicarious Surgical

Vicarious Surgical, Inc. engages in advancing the field of surgical robotics. Through the use of surgical robotics, the company aims to improve patients lives, surgeons abilities, and expand global access to high-quality care. The company was founded by Adam Sachs and Sammy Khalifa on May 6, 2020 and is headquartered in Waltham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vicarious Surgical reports progress in procedures and system development

Vicarious Surgical demonstrated strong performance in Q4 2022 with successful procedures and system advancements.
While facing financial challenges, the company's strategic strengths and opportunities position them for future growth.
Maintaining a balance between innovation, cost management, and regulatory milestones will be key for Vicarious Surgical.

Vicarious Surgical reports Q1 progress amidst regulatory discussions and innovation

Vicarious Surgical's Q1 2023 performance reflects progress in refining their robotic system and managing expenses, with a strong cash position and ongoing FDA discussions.
The company's strengths lie in innovation, regulatory focus, and strategic spending, positioning them well for future growth and expansion into new indications.
Challenges include high operating expenses and regulatory uncertainties, while opportunities exist in enhancing their technology and capitalizing on market potential through disciplined investments.

Vicarious Surgical reports Q2 loss, eyes FDA milestones for growth

Vicarious Surgical's Q2 performance reflects a focus on innovation, regulatory compliance, and strategic leadership.
The company's strong cash position, upcoming milestones, and product development efforts signal growth potential.
Challenges in managing expenses, regulatory hurdles, and market competition require careful navigation and strategic planning.
Opportunities lie in expanding partnerships, FDA approvals, and leveraging the demand for minimally invasive surgical solutions.

Vicarious Surgical reports improved finances but faces delays in flagship program

Vicarious Surgical navigated challenges with financial improvements but faces delays in their flagship program. Despite setbacks, the company remains committed to revolutionizing robotic surgery and enhancing capital efficiency.

Vicarious Surgical reports progress in product development and funding

Vicarious Surgical navigated challenges in 2023, strengthened its product offering, and secured funding for future growth. The company's financial position is stable, with a focus on achieving milestones in 2024. Leveraging partnerships and regulatory clarity present growth opportunities.

Vicarious Surgical reports strong Q1 performance and eyes global expansion

Vicarious Surgical's Q1 2024 performance reflects financial improvements and technological advancements, positioning the company for future growth.
While facing challenges in system integration and regulatory processes, the company's strengths in technology innovation and leadership provide a strong foundation for success.
Opportunities in international expansion, strategic partnerships, and regulatory advancements present avenues for Vicarious Surgical to capitalize on its unique market position and drive long-term value.

Vicarious Surgical reports Q2 progress amidst financial challenges

Vicarious Surgical's Q2 2024 performance showed progress in system integration and partnerships, but also highlighted financial challenges.
The company's strong cash position and focus on upcoming milestones position it well for future growth opportunities.
Analyst questions underscore the need for Vicarious Surgical to address financial concerns and execute on its strategic initiatives effectively.

Vicarious Surgical reports improved financials and progresses on robotic platform

Vicarious Surgical's Q3 2024 performance showed financial improvements and progress in developing its single-port platform for robotic surgery. While challenges and uncertainties exist, the company's focus on cost management and regulatory readiness bode well for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vicarious Surgical, Inc. a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It also designs surgical robotics. The company was founded by Adam Sachs, Sammy Khalifa, and Barry Greene on May 1, 2014 and is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to enhance patient outcomes and improve the cost and efficiency of surgical procedures, announced it has signed a strategic development agreement with Intermountain Health, a leading U.S. healthcare system. Intermountain Health is a nonprofit system of 33 hospitals, 385 clinics, medical groups with some 4,300 employed physi.

Vicarious Surgical Announces New Hospital System Partnership with Intermountain Health

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will present at the Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Management is scheduled to participate in a fireside chat on Thursday, September 21, 2023, at 10:00 am ET. Inte.

Vicarious Surgical to Present at the Gilmartin Group Emerging Growth Company Showcase

Vicarious Surgical is a surgical robotics company developing a next-generation surgical robot with human-like dexterity. The company has a large addressable market of over 45 million abdominal procedures worth $150 billion, but its survival is uncertain due to low cash reserves and high burn. I am personally staying on the sidelines as I believe the risk / reward is better if/when RBOT reaches commercialization with a superior product than currently awaiting regulatory approval.

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced the Company will participate in the Canaccord Genuity 43rd Annual Growth Conference. Management is scheduled to present on Wednesday, August 9 at 2:30 p.m. ET. A live webcast of the presentation will be accessible to the.

Vicarious Surgical to Present at the Canaccord Genuity 43rd Annual Growth Conference

Vicarious Surgical shares plunged more than 40% after the robotics technology company announced a public offering of its shares at a steep discount to its share price at the time.   The company said it was offering 45 million shares at a price of $1, far below its then-share price of about $1.65.

Vicarious Surgical stock tanks on discounted public offering

Vicarious Surgical (NYSE: RBOT ) stock is falling on Thursday after the surgical robot company revealed details of a public offering. That public offering has Vicarious Surgical selling 45 million shares of RBOT stock at a price of $1 per share.

Why Is Vicarious Surgical (RBOT) Stock Down 41% Today?

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the pricing of its underwritten public offering of 45,000,000 shares of its Class A common stock (“Common Stock”) at a price to the public of $1.00 per share. In addition, Vicarious Surgical has granted the underwrite.

Vicarious Surgical Announces Pricing of Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that it has commenced an underwritten public offering of $45.0 million of shares of its Class A common stock (“Common Stock”). All of the shares of Common Stock are being offered by Vicarious Surgical. In addition, th.

Vicarious Surgical Announces Launch of Proposed Public Offering

Vicarious Surgical Inc. (NYSE:RBOT ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Adam Sachs - Chief Executive Officer Bill Kelly - Chief Financial Officer Kaitlyn Brosco - Investor Relations Conference Call Participants Simran Kaur - Piper Sandler Ryan Zimmerman - BTIG Operator Good afternoon, and welcome to Vicarious Surgical's, Second Quarter 2023 Earnings Conference Call. My name is Sara, and I'll be your operator for today's call.

Vicarious Surgical Inc. (RBOT) Q2 2023 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, July 27, 2023. “Following our latest pre-submission meeting with the FDA, we are thril.

Vicarious Surgical Reports Second Quarter 2023 Financial Results and Announces Clinical Plan and Regulatory Intent

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the second quarter ended June 30, 2023, after the market closes on Thursday, July 27, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in.

Vicarious Surgical to Report Second Quarter 2023 Financial Results on July 27, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the promotion of John Mazzola to Chief Operating Officer. John joined Vicarious Surgical in March of 2022 as SVP of Operations and has over 35 years of medical device industry experience. He has been involved with ove.

Vicarious Surgical Announces Promotion of John Mazzola to Chief Operating Officer

Vicarious Surgical, Inc. (NYSE:RBOT ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kaitlyn Brosco - IR Adam Sachs - Co-Founder, CEO, President & Director William Kelly - CFO & Treasurer Conference Call Participants Kyle Rose - Canaccord Operator Good afternoon, and welcome to Vicarious Surgical's First Quarter 2023 Earnings Conference Call. My name is Alisa, and I will be your operator for today's call.

Vicarious Surgical, Inc. (RBOT) Q1 2023 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended March 31, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, May 8, 2023. “At Vicarious Surgical, we envision a future where exceptional surgical.

Vicarious Surgical Reports First Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2023, after the market closes on Monday, May 8, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in lis.

Vicarious Surgical to Report First Quarter 2023 Financial Results on May 8, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced that the company will be participating in the following upcoming investor conferences. Cowen 43rd Annual Healthcare Conference Fireside Chat on Wednesday, March 8th at 9:50 a.m.

Vicarious Surgical to Participate in Upcoming Conferences

Is this stock the next Intuitive Surgical? Maybe. We won't know for sure, though, until it has something to sell.

Why Vicarious Surgical Stock Just Popped 10%

Vicarious Surgical, Inc. (NYSE:RBOT ) Q4 2022 Earnings Conference Call February 13, 2023 4:30 PM ET Company Participants Kaitlyn Brosco - IR Adam Sachs - Co-Founder, CEO, President & Director William Kelly - CFO & Treasurer Conference Call Participants Ryan Zimmerman - BTIG Eric Anderson - Cowen and Company Adam Maeder - Piper Sandler & Co. Kyle Rose - Canaccord Genuity Operator Good afternoon, and welcome to the Vicarious Surgical's Fourth Quarter 2022 Earnings Conference Call. My name is Tia, and I will be your operator for today's call.

Vicarious Surgical, Inc. (RBOT) Q4 2022 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2022. Management will host a corresponding conference call at 4:30 p.m. ET today, February 13, 2023.

Vicarious Surgical Reports Fourth Quarter and Full Year 2022 Financial Results

WALTHAM, Mass.--( BUSINESS WIRE )--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 after the market closes on Monday, February 13, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Vicarious Surgical to Report Fourth Quarter and Full Year 2022 Financial Results on February 13, 2023

WALTHAM, Mass.--( BUSINESS WIRE )--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today.

Vicarious Surgical Announces Changes to Board of Directors

WALTHAM, Mass.--( BUSINESS WIRE )--Vicarious Surgical Inc. (“Vicarious Surgical'' or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced that renowned surgeon Igor Belyansky, MD, used the Vicarious Surgical Beta 2 prototype, to successfully perform two cadaveric ventral hernia repair procedures.

Vicarious Surgical Partners with Renowned Surgeon to Successfully Perform Two Cadaveric Ventral Hernia Procedures

Vicarious Surgical System Named to TIME's List of the Best Inventions of 2022

Vicarious Surgical Inc. (NYSE:RBOT ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Kaitlyn Brosco - Director, Investor Relations Adam Sachs - Co Founder & CEO Bill Kelly - Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to Vicarious Surgical's Third Quarter 2022 Earnings Conference Call. My name is Amber, and I will be your operator for today's call.

News for Vicarious Surgical Stock (RBOT)